Skip to main content
SpringerLink
Log in

Managementstrategien bei der oberen Einflussstauung

Management strategies for superior vena cava syndrome

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Die Therapie der oberen Einflussstauung hat sich in den letzten Jahren verändert. Nur bei sehr rascher Progredienz und schwerer Symptomatik besteht eine Notfallsituation, ist ein sofortiger Beginn der Therapie erforderlich. Gerade bei schwerer Symptomatik haben sich Gefäß-Stents als Behandlungskonzept etabliert, da sie eine sehr effektive und rasche Linderung des Beschwerdebilds ermöglichen. Die Wahl der onkologischen Therapie erfolgt anhand des histologischen Subtyps der malignen Erkrankung. In den meisten Fällen kann das Ergebnis der Biopsie abgewartet werden, die Diagnostik sollte jedoch umgehend durchgeführt und abgeschlossen werden.

Abstract

In recent years, therapeutic strategies in tumor-related superior vena cava syndrome have changed. Only patients with rapid progression of symptoms and those suffering heavily deserve emergency therapy. Vascular stenting has been established in the last decade as a very fast and effective therapy for occlusion of the superior vena cava, predominantly used for patients with these findings. Principles of therapy are based on the histologic subtype of the underlying malignant disease. In most cases therapy can be withheld until the histologic diagnosis is made, but all required diagnostic procedures should be completed as fast as possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1a–f
Abb. 2a, b
Abb. 3

Literatur

  1. Armstrong BA, Perez CA, Simpson JR, Hederman MA (1987) Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys 13:531–539

    CAS  PubMed  Google Scholar 

  2. Beck C, Berberich A, Bauknecht A, Schnabel K (1990) Die obere Einflußstauung als Notfall in der Strahlentherapie. Strahlenther Onkol 166:798–802

    CAS  PubMed  Google Scholar 

  3. Chan RH, Dar AR, Yu E, Stitt LW, Whiston F, Truong P, Vincent MD, Kocha W (1997) Superior vena cava obstruction in small-cell lung cancer. Int J Radiat Oncol Biol Phys 38:513–520

    Article  CAS  PubMed  Google Scholar 

  4. Citron ML, Fossiek BE, Krasnow SH, Johnston-Early A, Cohen MH (1983) Superior vena cava syndrome due to non-small-cell lung cancer. Resolution with chemotherapy alone. JAMA 250:71–72

    Article  CAS  PubMed  Google Scholar 

  5. Davenport D, Ferree C, Blake D, Raben M (1976) Response of superior vena cava syndrome to radiation therapy. Cancer 38:1577–1580

    CAS  PubMed  Google Scholar 

  6. de Gregorio Ariza MA, Gamboa P, Gimeno MJ, Alfonso E, Mainar A, Medrano J, Lopez-Marin P, Tobio R, Herrera M (2003) Percutaneous treatment of superior vena cava syndrome using metallic stents. Eur Radiol 13:853–862

    PubMed  Google Scholar 

  7. Dondelinger RF, Gofette P, Kurdziel J-C, Roche A (1991) Expandable metal stents for stenoses of vena cava and large veins. Sem Intervent Radiol 8:252–263

    Google Scholar 

  8. Elson JD, Becker GJ, Wholey MH, Ehrman KO (1991) Vena caval and central venous stenoses: Management with Palmaz ballon-expandable intraluminal stents. J Vasc Interv Radiol 2:215–223

    CAS  PubMed  Google Scholar 

  9. Kalra M, Gloviczki P, Andrews JC, Cherry KJ Jr, Bower TC, Panneton JM, Bjarnason H, Noel AA, Schleck C, Harmsen WS, Canton LG, Pairolero PC (2003) Open surgical and endovascular treatment of superior vena cava syndrome caused by nonmalignant disease. J Vasc Surg 38:215–223

    Article  PubMed  Google Scholar 

  10. Kane RC, Cohen MH, Broder LE, Bull MI (1976) Superior vena caval obstruction due to small cell anaplastic carcinoma. Response to chemotherapy. JAMA 235:1717–1718

    Article  CAS  PubMed  Google Scholar 

  11. Levitt SH, Jones TK, Kilpatrick SJ, Bogardus CR (1969) Treatment of malignant superior vena caval obstruction. A randomized study. Cancer 24:447–451

    CAS  PubMed  Google Scholar 

  12. Martin M, Baumgartner I, Kolb M, Triller J, Dinkel HP (2002) Fatal pericardial tamponade after wallstent implantation for malignant superior vena cava syndrome. J Endovasc Ther 9:680–684

    PubMed  Google Scholar 

  13. Oderich GS, Treiman GS, Schneider P, Bhirgani K (2000) Stent placement for treatment of central and peripheral venous obstruction: A long-term multi-institutional experience. J Vasc Surg 32:760–769 .

    Article  CAS  PubMed  Google Scholar 

  14. Ostler PJ, Clarke PD, Watkinson AF, Gaze MN (1997) Superior vena cava obstruction: A modern management strategy. Clin Oncol 9:83–89.

    CAS  Google Scholar 

  15. Otten TR, Stein PD, Patel KC, Mustafa S, Silbergleit A (2003) Thromboembolic disease involving the superior vena cava and brachiocephalic veins. Chest 123:809–812

    Article  PubMed  Google Scholar 

  16. Pereira JR, Martins SJ, Ikari FK, Nikaedo SM, Gampel O (1999) Neoadjuvant chemotherapy vs. radiotherapy alone for superior vena cava syndrome (SVCS) due to non-small-cell lung cancer (NSCLC): Preliminary results of a phase II trial. Europ J Cancer 35:260

    Article  Google Scholar 

  17. Rodrigues CI, Njo KH, Karim AB (1993) Hypofractionated radiation therapy in the treatment of superior vena cava syndrome. Lung Cancer 10:221–228

    CAS  PubMed  Google Scholar 

  18. Rosch J, Uchida BT, Hall LD, Antonovic R, Petersen BD, Ivancev K, Barton RE, Keller FS (1992) Gianturco-Rosch expandable Z-stents in the treatment of superior vena cava syndrome. Cardiovasc Intervent Radiol 15:319–327

    CAS  PubMed  Google Scholar 

  19. Rowell NP, Gleeson FV (2003) Steroid, radiotherapy chemotherapy and stents for superior vena cava obstruction in carcinoma of the bronchus (Cochrane Review). The Cochrane Library, No. CD001316, Issue 3. Oxford: Update Software

  20. Sörensen JB, Stenbygaard LE Dahlberg J, Engelholm SA (1997) Short fraction radiotherapy for superior vena cava syndrome (SVCS) in 148 lung cancer patients. Lung Cancer 18:125

    Article  Google Scholar 

  21. Spiro SG, Shah S, Harper PG, Tobias JS, Geddes DM, Souhami RL (1983) Treatment of obstruction of the superior vena cava by combination chemotherapy with and without irradiation in small cell carcinoma of the bronchus. Thorax 38:501–505

    CAS  PubMed  Google Scholar 

  22. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T, Fukuda H, Saijo N (2002) Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20:3054–3060

    Article  CAS  PubMed  Google Scholar 

  23. Turrisi A T III, Kyungman A, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH (1999) Twice daily compared to once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265–271

    Google Scholar 

  24. Urban T, Lebeau B, Chastang C, Leclerc P, Botto MJ, Sauvaget J (1993) Superior vena cava syndrome in small cell lung cancer. Arch Int Med 153:384–387

    Article  CAS  Google Scholar 

  25. van Houtte P, de Jager R, Lustman-Marechal J, Kenis Y (1980) Prognostic value of the superior vena cva syndrome as the presenting sign of small cell anaplastic carcinoma of the lung. Eur J Cancer 16:1447–1450

    PubMed  Google Scholar 

  26. Warde P, Payne D (1992) Does thoracic irradiation improve survival and local control in limited-stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10:890–895

    CAS  PubMed  Google Scholar 

  27. Würschmidt F, Bünemann H, Heilmann HP (1995) Small cell lung cancer with and without superior vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases. Int J Radiat Oncol Biol Phys 33:77–82

    PubMed  Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Klinik für Radioonkologie und Strahlentherapie, Charité, Campus Benjamin Franklin, Berlin

    S. Höcht, D. Bottke & W. Hinkelbein

  2. Fachkrankenhaus für Lungenheilkunde und Thoraxchirurgie, Berlin-Buch

    K.-M. Deppermann

  3. Klinik für Radioonkologie und Strahlentherapie, Charité, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 , Berlin

    S. Höcht

Authors
  1. S. Höcht
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K.-M. Deppermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Bottke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Hinkelbein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Höcht.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Höcht, S., Deppermann, KM., Bottke, D. et al. Managementstrategien bei der oberen Einflussstauung. Onkologe 10, 325–333 (2004). https://doi.org/10.1007/s00761-004-0695-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-004-0695-2

Schlüsselwörter

Keywords

Search

Navigation